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CardiomyopathyOur aim was to explore the dose-dependent diastolic dysfunction and the mechanisms of heart failure and
early death in transgenic (TG) mice modeling human restrictive cardiomyopathy (RCM). The ﬁrst RCM
mouse model (cTnI193His mice) carrying cardiac troponin I (cTnI) R193H mutation (mouse cTnI R193H equals
to human cTnI R192H) was generated several years ago in our laboratory. The RCM mice manifested a phe-
notype similar to that observed in RCM patients carrying the same cTnI mutation, i.e. enlarged atria and re-
stricted ventricles. However, the causes of heart failure and early death observed in RCM mice remain
unclear. In this study, we have produced RCM TG mice (cTnI193His-L, cTnI193His-M and cTnI193His-H) that ex-
press various levels of mutant cTnI in the heart. Histological examination and echocardiography were
performed on these mice to monitor the time course of the disease development and heart failure. Our
data demonstrate that cTnI mutation-caused diastolic dysfunction is dose-dependent. The key mechanism
is myoﬁbril hypersensitivity to Ca2+ resulting in an impaired relaxation in the mutant cardiac myocytes.
Prolonged relaxation time and delay of Ca2+ decay observed in the mutant cardiac myocytes are correlated
with the level of the mutant protein in the heart. Markedly enlarged atria due to the elevated end-diastolic
pressure and myocardial ischemia are observed in the heart of the transgenic mice. In the mice with the
highest level of the mutant protein, restricted ventricles and systolic dysfunction occur followed immediately
by heart failure and early death. Diastolic dysfunction caused by R193H troponin I mutation is speciﬁc, show-
ing a dose-dependent pattern. These mouse models are useful tools for the study of diastolic dysfunction. Im-
paired diastole can cause myocardial ischemia and ﬁbrosis formation, resulting in the development of systolic
dysfunction and heart failure with early death in the RCM mice with a high level of the mutant protein in the
heart.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
Cardiomyopathy is a disorder that primarily affects cardiac muscles
resulting in cardiac dysfunctions [1–3]. Among various types of cardio-
myopathies, hypertrophic cardiomyopathy (HCM) and restrictive
cardiomyopathy (RCM) share a similar key feature characterized by a, hypertrophic cardiomyopathy;
ation time; IVCT, isovolumetric
ning; LVEDD, left ventricle end
me.
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td. Open access under CC BY-NC-SA lidiastolic dysfunction [4–6]. Unlike HCM, RCM is rare accounting roughly
for 2–5% of all inherited cardiomyopathies. However, the prognosis of
the disease, especially in young patients with RCM, is poor, as this con-
dition often leads to heart failure and early death [7]. Treatment of
RCM is difﬁcult and often ineffective [8,9]. A linkage study had, for the
ﬁrst time, demonstrated that idiopathic RCM can be a part of clinical ex-
pression of six cardiac troponin I (cTnI)mutations [5]. Among thosemu-
tations, two of the mutations (K178E and R192H) identiﬁed in young
individuals were de novo mutations with the worst clinical phenotype
[5]. The ﬁrst transgenic (TG) mouse model (cTnI193His mice) carrying
the RCM cTnI mutation (Arg193His in mouse cTnI protein that equals
to human cTnI R192H)was generated several years ago in our laborato-
ry [10]. The RCM TG mice manifested a phenotype similar to that ob-
served in RCM patients carrying the same cTnI mutation, i.e. markedly
enlarged atria and restricted ventricles due to the increased ventricular
pressure and stiffness [11]. The cell-based studies further revealed that
the key defect in RCM cardiac myocytes was impaired relaxation thatcense.
Fig. 1. Determination of the mutant cTnI (cTnI R193H) replacement in the hearts from
various RCM transgenic lines. (A)Westernblotting analysis using two speciﬁcmonoclonal
antibodies, mAb 4H6 recognizes wild type (WT), cTnI R193H, but not slow skeletal TnI
(ssTnI) from soleus muscle; mAb TnI-1 recognizes WT cardiac and skeletal TnI but not
cTnI R193H. Cardiac troponin T (cTnT) was used as protein loading control. (B) Summary
of Western blotting results and values are expressed as means ± SD from 4 separate ex-
periments. (C) Kaplan–Meier survival curves for WT (n = 18), cTnI193His-L (n = 18),
cTnI193His-M (n = 12) and cTnI193His-H (n = 17) mice. The log-rank test indicates statis-
tically signiﬁcant differences among the four survival curves (P b 0.05). The observation
was performed for 90 days and 100% death was observed in cTnI193His-H mice at age of
1 month.
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the RCM mouse model is well characterized, several questions still re-
main. The questions we aim to address in this study are: 1) What is
the cause of the varied severity of the disease observed in patients suf-
fering from cardiomyopathies caused by myoﬁbril protein mutations?
Is the cardiac dysfunction caused by cTnI mutation dose-dependent,
i.e. does the impaired relaxation depend on the level of themutant pro-
tein in the heart? 2)We observed thatmost RCM cTnI TGmice had early
onset of impaired relaxation followed by heart failure at a later stage.
What is the mechanism that correlates the early diastolic dysfunction
to late stage heart failure? 3) What are the causes of death in RCM
cTnI TG mice? Is it congestive heart failure, arrhythmia, or both?
Clinically, these questions have not beenwell answered to date. This
is because of the lack of quantitative data of the mutant protein in dis-
eased hearts due to the limited cardiac samples from patients, and the
lack of speciﬁc antibodies that differentiate mutant proteins from wild
type proteins. In the present study, we have produced RCM cTnI TG
mice that express various levels of mutant cTnI in the heart by crossing
our cTnI knockout mice with RCM TG cTnI193His mice. Histological ex-
amination and echocardiography were performed on these TG mice at
different time points to monitor the progress of the disease and to de-
termine simultaneously the myocardial ischemia, ﬁbrosis and the
damage-caused cardiac dysfunction and heart failure. Our data demon-
strate, for the ﬁrst time, that cTnImutation-caused diastolic dysfunction
is dose-dependent andmyocardial ischemia caused by impaired diasto-
le is probably associated with the late development of systolic dysfunc-
tion resulting eventually in heart failure and early death in RCM.
2. Methods
This investigation conforms to the Guide for the Care and Use of
Laboratory Animals (NIH Pub. No. 85-23, revised 1996) and was in ac-
cordance with the protocols approved by the Institutional Animal
Care and Use Committees at Florida Atlantic University.
2.1. Animals
The cTnI gene knockout mice (C57BL/6) were generated previ-
ously and are well characterized [14]. The heterozygous cTnI knock-
out (cTnI+/−) mice are maintained in our laboratory for more than a
decade. These mice were paired with transgenic cTnI193His mice
(C57BL/6) that exhibit a RCM phenotype [10]. By crossing cTnI+/-
mice with cTnI193His mice, we produced cTnI193His/cTnI+/− double
transgenic mice. By crossing these double transgenic mice, we
obtained the transgenic mice expressing various levels of cTnI
R193H in the heart: cTnI193His-H mice that express only mutant
cTnI R193H at a wild type cTnI null background and cTnI193His-M
mice that express about 40% of mutant cTnI with 60% of wild type
cTnI. The cTnI193His-L is our original transgenic mouse line that ex-
presses about 20% of mutant cTnI in the heart. The wild type (WT,
C57BL/6) mice were used as controls in the study and they have
the same genomic background as the transgenic mice. A PCR-based
assay was performed to determine the genotypes and the mutant
protein replacement rate in most of the experimental animals was
conﬁrmed by Western blotting assays after the experiments.
2.2. Determination of the replacement rate of the mutant cTnI in the
heart by Western blotting
Cardiac myoﬁlament proteins were extracted and the incorpora-
tion rate of wild type and mutant cTnI in cardiac myoﬁbrils were de-
termined by Western blotting as described previously [11,12]. Brieﬂy,
cardiac myoﬁbril proteins were examined on SDS-PAGE and Western
blotting using two mouse monoclonal antibodies (mAb). TnI-1 anti-
body is speciﬁc for the C-terminal epitope of TnI involving the residue
of R193 and 4H6 antibody recognizes an epitope in the middle regionof cTnI polypeptide chain. The cTnI R193Hmutation destroyed the TnI-1
epitope but not the 4H6 epitope, allowing the distinction between cTnI
WT and R193H. For Western blotting, cardiac ventricles were homoge-
nized in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer containing 2% SDS to extract myoﬁlament proteins. The protein
bands were transferred to a nitrocellulose membrane using a Bio-Rad
Lab semidry electrotransfer apparatus. The nitrocellulose membrane
was blocked with 1% bovine serum albumin in Tris-buffered saline
and incubated with mAbs diluted in TBS-T containing 0.1% bovine
serum albumin. Antibodies on immunoblots were visualized by en-
hanced chemiluminescence (ECL detection kit from GE Healthcare).
Cardiac TnT (cTnT) was used as an internal control to normalize
the protein sample loading. For quantiﬁcations, the protein bands
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the same blot.2.3. Contractility measurements in isolated cardiac myocytes
Mouse cardiac myocytes were isolated using a Langendorff Per-
fusion Cell Isolation System (Cellutron Life Technology, Baltimore,
MD) and cultured in the medium provided by the same company.
Only the rod-shaped cells with clear edges and well-deﬁned sarco-
mere structure and without sarcolemmal blebs or spontaneous con-
tractions were used for the experiments. The mechanical properties
of cardiac myocytes were determined using an IonOptix Myocam
system (IonOptix Inc., Milton, MA). Cardiac myocytes were loaded into
the perfusion chambermounted on themicroscope stage and superfused
(1 ml/min, 37 °C)with Tyrode solution containing (inmM): 131 NaCl, 4
KCl, 1 CaCl2, 1 MgCl2, 10 glucose and 10 HEPES, at pH 7.4. The cells were
ﬁeld stimulated at 8 V at a frequency of 0.5 Hz. Sarcomere shortening
was measured and at least 8 contraction cycles were used for analysis
as described previously [12].Fig. 2. Cell-based assays to measure myocardial contractility. (A) Representative
raw sarcomere shortening recordings on cardiac myocytes isolated from wild
type (WT) and various transgenic (TG) mice (cTnI193His-L, cTnI193His-M and
cTnI193His-H). The rightward shift (prolonged relaxation) caused by RCM cTnI mu-
tation is dose-dependent. (B) Dose-dependent end-diastolic sarcomere length.
(C) Summary of 90% sarcomere length relaxation time. No signiﬁcant changes were ob-
served in sarcomere shortening fraction (D) and 90% sarcomere length shortening time
(E) among the tested groups. Values are expressed asmeans ± SE fromat least 3 separate
experiments (n = 22–25 cells per group). Statistical signiﬁcance was determined by
ANOVA followed by post hoc Newman–Keuls (SNK) tests. *P b 0.05 compared to WT.
†P b 0.05 compared to cTnI193His-L. ‡P b 0.05 compared to cTnI193His-M.
Fig. 3. Cell-based assays tomeasure Ca2+ transients in isolated cardiacmyocytes. (A) Rep-
resentative raw Ca2+ transients obtained from cardiac myocytes isolated from wild type
(WT) and various transgenic (TG)mice (cTnI193His-L, cTnI193His-Mand cTnI193His-H). A sig-
niﬁcant slowing of Ca2+ decay was observed in RCM TG cardiac myocytes showing a
dose-dependent manner. Summary of Ca2+ transients at end-diastolic stage (B), time to
90% Ca2+ decay (C), peak amplitude of Ca2+ transients (D) and time to 90% Ca2+ peak
(E). Values are expressed as means ± SE from at least 3 separate experiments (n =
22–25 cells per group). Statistical signiﬁcance was determined by ANOVA followed
by post hoc Newman–Keuls (SNK) tests. *P b 0.05 compared to WT.
Fig. 4. Normalized pCa-force relationship in skinned cardiac muscle ﬁbers. The
pCa-force relationship was measured in skinned cardiac muscle ﬁbrils isolated from
hearts of WT, cTnI193His-L and cTnI193His-M mice. pCa50 values (WT, 5.89 ± 0.02,
cTnI193His-L, 6.02 ± 0.02, cTnI193His-M, 6.10 ± 0.03) are signiﬁcantly increased in
transgenic mice compared to the WT (P b 0.05) showing a signiﬁcant leftward shift
of the curves. Furthermore, the pCa50 values in cTnI193His-M group are signiﬁcantly
higher than those of the cTnI193His-L mice (P b 0.05), indicating a dose-dependent
manner of Ca2+ hypersensitivity in cTnI R193H mutation. Results are presented as
means ± SE (n = 6–7). Statistical signiﬁcance was determined by ANOVA followed
by post hoc Newman–Keuls (SNK) tests.
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The intracellular calcium transients were alsomeasured by IonOptix
Myocam system. Freshly isolated mouse cardiac myocytes were loaded
with 2 μM of Fura-2 AM (Molecular Probes) at room temperature for
20 min in loading buffer as described previously [12]. After 20 min of
de-esteriﬁcation of Fura-2 AM, the cells were superfused in Tyrode so-
lution and electrically stimulated at 8 V at a frequency of 0.5 Hz. For
measurement of Ca2+ transients, the cells were excited by UV light
(360 and 380 nm, alternately). The Fura-2 emission at 510 nmwas col-
lected with a photomultiplier tube. The kinetics of Ca2+ transients was
analyzed in conjunctionwithmyocytemechanicalmeasurements using
the software IonWizard 6.0.
Myoﬁbril Ca2+ sensitivity was determined by measuring pCa-force
curves in skinned myoﬁbrils isolated from WT or TG mouse hearts as
described previously [12].
2.5. Echocardiography
Echocardiography studies were performed by using a Vevo 770
High-Resolution In Vivo Imaging System (VisualSonics, Toronto, ON,
Canada) in our laboratory as described previously [15]. To decrease
experimental bias, all of the echocardiography measurements were
performed by an examiner blinded to the genotype. Experimental
mice were anesthetized with isoﬂurane at a concentration of 3%
and then maintained at 1% isoﬂurane by a facemask during the
whole procedure. Hair on the precordial region was cleanly removed
with Nair lotion hair remover (Church & Dwight Canada, Mississauga,
ON, Canada), and the region was covered with ultrasound transmission
gel (Aquasonic, Parker Laboratory, Fairﬁeld, NJ). Short-axis imageswereTable 1
Cardiac function measurements with echocardiography.
WT cTnI193H
Parameters
Body weight (g) 13.37 ± 0.39 12.85
Heart rate (bpm) 483 ± 3 468
Atria
LAEDD (mm) 1.78 ± 0.05 1.39
LAESD (mm) 1.12 ± 0.03 0.98
RAEDD (mm) 1.76 ± 0.06 1.94
RAESD (mm) 1.21 ± 0.01 1.25
LV end diastole
IVS (mm) 0.55 ± 0.01 0.48
LVEDD (mm) 3.21 ± 0.06 3.09
LV PW (mm) 0.60 ± 0.02 0.67
LV volume (μl) 41.58 ± 1.77 37.82
LV end systole
IVS (mm) 1.12 ± 0.06 0.98
LVESD (mm) 1.51 ± 0.05 1.61
LV PW (mm) 1.15 ± 0.01 1.04
LV volume (μl) 6.32 ± 0.54 7.37
Ejection fraction % 84.90 ± 0.69 80.45
Fractional shortening % 52.92 ± 0.76 48.01
Cardiac output (ml/min) 17.13 ± 0.49 14.77
Lv mass corrected, mg 40.98 ± 1.60 39.60
Mitral Pulse Doppler
E velocity (mm/s) 761.50 ± 16.75 753.63
A velocity (mm/s) 659.58 ± 8.29 630.39
E/A 1.16 ± 0.01 1.22
MV DT (ms) 15.00 ± 0.51 16.96
LV IVRT (ms) 13.73 ± 0.36 16.86
LV IVCT (ms) 6.96 ± 0.32 6.97
E/E′ 22.56 ± 0.69 20.28
Values are expressed as means ± SE from at least 8–10 mice (4-week old) per group. Statist
tests.
⁎ P b 0.05 compared to WT.
† P b 0.05 compared to cTnI193His-L.
‡ P b 0.05 compared to cTnI193His-M.taken to view the LV and RV movement during diastole and systole,
allowing us to measure the ventricular structure and dimension.
Transmitral blood ﬂow was observed with Pulse Doppler and diastolic
mitral annulus velocity was observed in Tissue Doppler. Coronary
blood ﬂowwas measured by applying Pulse Doppler with a modiﬁed
long-axis view, which enabled us to see the left main coronary artery
generating from the aorta and going between the left ventricle ante-
rior wall and the right ventricular outﬂow tract. All data and images
were saved and analyzed with the Advanced Cardiovascular Package
Software (VisualSonics, Toronto, ON, Canada) using an automated
analysis or semi-automated analysis to evaluate the cardiac function.
2.6. Telemetric ECG recording
ECG data were collected in the conscious, free-moving mice by
implanting a wireless telemetry device (TA10ETA-F20, Data Science
International (DSI), St. Paul, MN). Mice were anesthetized by
isoﬂurane inhalation and the implantable transmitter units were se-
cured in mice peritoneal cavities. The two electrical leads were lying
ﬂat and straight subcutaneously and positioned in a lead II orienta-
tion, in which the negative lead (clear) was placed in the area of
the right shoulder and the positive lead (red) immediately to the
left of the xyphoid space and caudal to the rib cage. The implanted
mice were housed separately in cages and biopotentials were trans-
mitted from within the animals via radio-frequency signals to the
underneath antenna receivers connected to a computer system for
24-hour data recording. ECG data of the ﬁrst 7 days after surgery were
disregarded considering the possible effects of anesthesia and surgical
procedures. Unﬁltered ECG data was acquired at 10 s intervals and
ECG waveforms and parameters were analyzed with a DSI analysisis-L cTnI193His-M cTnI193His-H
± 0.59 12.49 ± 0.64 14.11 ± 0.74
± 6 481 ± 4 483 ± 3
± 0.10⁎ 1.75 ± 0.08 2.55 ± 0.10⁎,†,‡
± 0.03 1.15 ± 0.07 2.03 ± 0.10⁎,†,‡
± 0.10 2.06 ± 0.16 3.58 ± 0.40⁎,†,‡
± 0.03 1.40 ± 0.13 3.34 ± 0.31⁎,†,‡
± 0.03 0.55 ± 0.05 0.57 ± 0.04
± 0.06 3.03 ± 0.12 2.47 ± 0.18⁎
± 0.02 0.68 ± 0.03 0.61 ± 0.02
± 1.67 36.14 ± 3.53 21.94 ± 4.03⁎,†,‡
± 0.01 1.02 ± 0.04 0.99 ± 0.01
± 0.08 1.47 ± 0.09 1.40 ± 0.10
± 0.03 1.03 ± 0.04 1.01 ± 0.02⁎
± 1.00 5.87 ± 0.87 5.15 ± 1.00
± 2.81 83.88 ± 1.09 76.55 ± 0.72⁎,‡
± 2.97 51.59 ± 1.21 43.39 ± 0.58⁎,‡
± 0.72 15.03 ± 1.23 7.56 ± 1.93⁎,†,‡
± 0.96 41.40 ± 1.27 29.18 ± 1.80⁎,†
± 26.48 712.16 ± 15.95⁎ 530.86 ± 51.42⁎,†
± 39.94 576.81 ± 24.19⁎ 489.09 ± 65.72
± 0.08 1.23 ± 0.02 1.11 ± 0.05
± 0.92 16.25 ± 0.81 17.74 ± 1.67
± 0.95 17.46 ± 0.56⁎ 24.08 ± 0.69⁎,†,‡
± 0.26 6.94 ± 0.40 9.22 ± 0.59⁎,†,‡
± 1.11 24.89 ± 3.23 31.97 ± 1.26⁎,†
ical signiﬁcance was determined by ANOVA followed by post hoc Newman–Keuls (SNK)
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were inspected for ischemia and arrhythmia by at least two indepen-
dent observers.
2.7. Histological examination
For light microscopy, mouse hearts were quickly excised after eutha-
nasia, perfused through the aorta with PBS for 1 min and ﬁxed in 10%
neutral buffered formalin solution (Sigma). Fresh lung and liver tissues
were washed with PBS and directly immersed in the same ﬁxation solu-
tion. The ﬁxed tissues went through a series of graded ethanol baths to
be dehydrated then into xylene. After being embedded with parafﬁn,
the tissues were sectioned into 5 μm thick slices, stained with hematoxy-
lin and eosin, and then viewed under an Olympus IX71 microscope.
Gomori's trichrome staining was also performed to detect ﬁbrosis in the
heart sections as described previously [14].
3. Results
3.1. Phenotype of the transgenic mice with different levels of the mutant
cTnI R193H
Heterozygous cTnI knockout mice and the original transgenic
cTnI193His mice (cTnI193His-L) were previously generated and charac-
terized in our laboratory [10–12,15]. By crossing cTnI+/- mice withFig. 5. Cardiac function measurement in RCM TG mice. Echocardiography and Doppler imagi
cTnI193His-H) at different time points (27-day-old and 3-month-old). Both diastolic function, s
left ventricular end diastolic volume (C), and systolic function, such as isovolumetric contrac
are expressed as means ± SE from at least 8–10mice per group. Statistical signiﬁcancewas det
to WT. †P b 0.05 compared to cTnI193His-L. ‡P b 0.05 compared to cTnI193His-M.cTnI193His mice, we generated cTnI+/−/cTnI193His double transgenic
mice. Then by crossing these double transgenic mice, we obtained
cTnI193His-M mice that expresses about 38% mutant cTnI R193H and
has a heterozygous cTnI gene knockout background. By further cross-
ing the cTnI193His-M mice, we obtained cTnI193His-H mice that express
about 80%mutant cTnI R193H in a cTnI null background (Fig. 1).West-
ern blotting data conﬁrmed the incorporation rates of wild type cTnI
and themutant cTnI R193H in cardiac myoﬁlaments from these differ-
ent transgenic mouse lines (Fig. 1). At the age of 3 weeks, no ssTnI
could be detected in the ventricles from the WT, cTnI193His-L or
cTnI193His-M mice, however, a small portion of ssTnI was detected in
cardiac myoﬁlaments from the cTnI193His-H mice (Fig. 1). This is con-
sistent with what we observed in heterozygous cTnI knockout mice
in which the expression of ssTnI is extended as a compensation for
the deﬁciency of the wild type cTnI in young mice [14]. No signiﬁcant
effect on cell contraction and relaxation has been observed in cardiac
myocytes containing the small portion of ssTnI [14]. Kaplan–Meier surviv-
al curves demonstrated dramatic differences among the mice expressing
different levels of the mutant protein. Based on observations for the ﬁrst
3 months, no mice in cTnI193His-H group survived over 30 days after
birth, while the survival rates were 78% in the cTnI193His-M group and
97% in the cTnI193His-L group. The earliest death in cTnI193His-H mice oc-
curred on day 21 after birth, however most of them died on days 27–30
(Fig. 1C). Bi-atrial enlargement was a signiﬁcant cardiac morphological
change observed in these mice as reported previously [12].ng were performed on wild type (WT) and RCM TG mice (cTnI193His-L, cTnI193His-M and
uch as isovolumetric relaxation time (A), left ventricular end diastolic dimension (B) and
tion time (D), ejection fraction (E) and fractional shortening (F), were measured. Values
ermined by ANOVA followed by post hoc Newman–Keuls (SNK) tests. *P b 0.05 compared
Fig. 6. Comparison of the time-course of changes in diastolic function and systolic func-
tion in RCM TG mice. (A) The sign of impaired relaxation manifested as the prolonged
isovolumetric relaxation time occurred early on cTnI193His-H mice on day 21 after birth
and became worse during the progress of the disease. (B) Ejection fraction as a contrac-
tion index was determined on wild type (WT) and cTnI193His-H mice from day 21 to
day 29. A signiﬁcant change in systolic dysfunction was not observed on cTnI193His-H
mice until the age of 27 days. Values are expressed as means ± SE from at least 8–10
mice per group. Statistical signiﬁcance was determined by ANOVA followed by post
hoc Newman–Keuls (SNK) tests. *P b 0.05 compared to WT.
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Our previous studies indicate that prolonged relaxation caused by
the increased myoﬁbril sensitivity for Ca2+ is the major mechanism in
cTnI R193H caused diastolic dysfunction [11,12]. The cell-based assays
further conﬁrmed that the impaired relaxation was speciﬁcally caused
by cTnI R193H mutation, showing a dose-dependent manner (Fig. 2).
The sarcomere contraction (shortening) time did not have signiﬁcant
change among the cardiac myocytes from the different TG mice ex-
pressing different levels of the mutant protein. However, the sarco-
mere relaxation time was signiﬁcantly prolonged in TG myocytes in
a dose-dependent manner (Fig. 2). The end-diastolic sarcomere
length was signiﬁcantly shortened in TG myocytes compared to the
WT (Fig. 2). Correspondingly, the intracellular Ca2+ decay time
was also prolonged signiﬁcantly with increasing levels of mutant
protein in the myocardial cells (Fig. 3). The myoﬁbril sensitivity to
Ca2+ was signiﬁcantly enhanced in the mutant myoﬁbrils compared
to the WT myoﬁbrils showing a dose-dependent manner (Fig. 4).
3.3. Dose-dependent cardiac dysfunction in mice expressing various
levels of the mutant protein
Echocardiography studies also showed a dose-dependent cardi-
ac dysfunction in the TG mice expressing various levels of the mu-
tant protein (Table 1). More obviously, the cTnI193His-H mice at the
age of 4 weeks showed a signiﬁcant prolongation of left ventricular
isovolumetric relaxation time (IVRT) and a dramatic reduction of
left ventricular end diastolic dimension (LVEDD) and volume
(LVEDV)(Table 1). Both ejection fraction and fractional shortening
were signiﬁcantly reduced in these mice at the age of 4 weeks
(Fig. 5 and Table 1). However, the TG mice from cTnI193His-L and
cTnI193His-M groups did not show any signiﬁcant change at this
age compared to the WT (Fig. 5) except for a signiﬁcant prolonged
IVRT in cTnI193His-M mice (Table 1). The signiﬁcantly reduced
LVEDD and LVEDV were observed in cTnI193His-L and cTnI193His-M
mice at the age of 3 months (Fig. 5),
Impaired diastolic function with a normal or near normal systolic
function is the hallmark of RCM. The prolonged IVRT was ﬁrst ob-
served with Doppler on cTnI193His-H mice at age of 21 days and on
cTnI193His-M mice at age of 4 weeks (Fig. 6A and Table 1). This is con-
sistent with the reports that IVRT is the most sensitive Doppler index
to detect impaired relaxation because it is the ﬁrst to become abnor-
mal [16,17]. In addition, the occurrence time of the altered IVRT is de-
pendent on the levels of the mutant protein in the heart. Besides, a
damaged systolic function characterized by a signiﬁcant reduction
of ejection fraction in these mice did not occur until day 27 after
birth (Fig. 6B). These data suggest that impaired relaxation is the orig-
inal defect caused by cTnI mutation in these TG mice. Nevertheless,
the systolic dysfunction occurred in these mice at the end-stage of
the disease.
3.4. Mechanisms underlying the development of systolic heart failure in
TG mice
To further explore how and why a diastolic dysfunction eventually
develops into a systolic dysfunction in these TGmice, we performedhis-
tological examination on various organ samples from the TGmice at dif-
ferent times. The data showed that on day 23 after birth the cTnI193His-H
mice were still active. Although bi-atrial enlargement was evident at
this time as reported previously due to the increased ventricular pres-
sure, the histological examination of cardiac samples showed a little
myocardial atrophy and limited ﬁbrosis (Fig. 7). Histological examina-
tions of the lungs and liver did not show any signiﬁcant damage
(Fig. 7). These data suggest that limited cell death might occur in
these hearts with diastolic dysfunction, since systolic function was still
preserved at this time, which coincided with a normal ejection fractionobserved by echocardiography (Fig. 6B). On day 27 after birth when the
mice presented signiﬁcant mortality, histological examination of cardi-
ac tissues from the cTnI193His-H mice showed a dramatic myoﬁbril dis-
array and massive ﬁbrosis. Signiﬁcant pulmonary and hepatic edema
was observed in thesemice at the age of 27 days (Fig. 7), indicating con-
gestive heart failure in these TGmice. The development of systolic dys-
function in cTnI193His-M mice was much delayed since no signiﬁcant
decrease of EF and FS was observed in these mice before the age of
8 months (Table 2).
To further conﬁrm that myocardium ischemia occurs in the TG
mouse hearts, we directly measured the coronary blood ﬂow on
23-day-old cTnI193His-H andWTmice. The TGmice showed a signiﬁcant
decrease of blood ﬂow in left main coronary artery, as indicated by a
disappeared systolic peak and a signiﬁcantly lowered diastolic peak in
Doppler observations (Fig. 8 and Table 3). The data indicate that al-
thoughno signiﬁcant changes are observed in ejection fraction and frac-
tional shortening, the coronary blood supply is signiﬁcantly reduced
due to the impaired diastole in the TG hearts.
3.5. Telemetric ECG observations
ECG recording using a telemetric system was performed on con-
scious, free-moving cTnI193His-H mice starting on day 23 after birth
and continuing till their death (most on days 28–30). The signiﬁcant
abnormality observed in 6 cTnI193His-H mice was a depressed S–T seg-
ment (Fig. 9), suggesting myocardial ischemia. No signiﬁcant arrhyth-
mia or vibration was observed in these mice, except for a few times,
arrhythmia was observed just a couple of hours before death. A grad-
ually developed bradycardia was also noticed during the telemetric
ECG recording (Fig. 9). The mechanism of the bradycardia observed
on these mice is not clear. It is probably a compensatory mechanism
against the impaired cardiac relaxation.
4. Discussion
Heart failure is a leading cause of morbidity and mortality in the
U.S. Single cardiac myoﬁbril gene mutations are associated with
Fig. 7.Morphological and histological examination of the heart, lungs and liver from RCM TG mice. Five 27-day-old wild type (WT), ﬁve cTnI193His-H mice at age of 23 days and ﬁve
cTnI193His-H mice at age of 27 days were used for morphological and histological studies. The ﬁrst panel shows the gross morphology of the hearts and bi-atrial enlargement is ev-
ident in RCMmice. In the second panel, the H-E staining of cardiac sections shows dramatic myoﬁbril disarrays in the heart samples from cTnI193His-H mice at age of 27 days. In the
third panel, the trichrome staining shows a spotted ﬁbrosis (green staining) observed in cTnI193His-H mouse hearts at age of 23 days, whereas massive ﬁbrosis was observed in the
heart samples from cTnI193His-H mice at age of 27 days. Signiﬁcant pulmonary (the fourth panel) and hepatic (the ﬁfth panel) edema and congestion were observed in the lung and
liver samples from cTnI193His-H mice at age of 27 days.
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cardiomyopathy (HCM) and RCMshare the samemechanismof diastol-
ic dysfunction [18]. Diastolic dysfunction is an important clinical prob-
lem since up to 40% of heart failure cases are due to diastolic
dysfunction. We have generated TG mice expressing RCM mutant cTnI
in the heart to investigate the mechanisms connecting the profound
deﬁcits inmyoﬁlament function to the development of cardiac dysfunc-
tion associated with heart failure. The signiﬁcant signs of diastolic dys-
function in RCM cTnI193His mice are markedly enlarged atria caused by
the increased ventricular pressure and an increased IVRT, which is the
earliest sign detected by echocardiography in RCM [11,12,16]. The
data from analyzing in vitro reconstituted thin ﬁlaments showed that
the RCM cTnImutations had high Ca2+-sensitizing effects on force gen-
eration [19,20]. Davis et al. used an acute genetic engineeringmethod to
transfer the RCM mutant cTnI genes into isolated adult rat cardiac
myocytes and found that permeabilized myocyte Ca2+ sensitivity was
increased [21]. In our study, we have shown a dose-dependentmyoﬁbril hypersensitivity to Ca2+ accompanied with a prolongation
of the relaxation time and a delay of Ca2+ decay in TG cardiac myocytes
expressing various levels of cTnI R193H. Our data are consistent with
our previous reports [11,12] and reports from other studies [19–21].
In the present study, we demonstrate that RCM cTnI R193H muta-
tion causes a dose-dependent diastolic dysfunction in experimental
mice. The severity and the onset time of the impaired relaxation
(prolonged relaxation time and increased IVRT due to prolonged
Ca2+ decay in myoﬁbrils) are dependent on the amount of mutant
cTnI in the heart. In cTnI193His-H group, the TG mice cannot tolerate
the cardiac dysfunction since cTnI193His-H mice have 80% mutant
cTnI R193H in the heart. The impaired relaxation and the change of
IVRT occur the earliest in these mice. The disease progresses quickly
in these animals leading to 100% early death by the age of 30 days.
The altered IVRT is observed as well in cTnI193His-M mice at the age
of 4 weeks and in cTnI193His-L mice at the age of about 2 months
[10]. The dose-dependent phenotype in transgenic mice suggests
Table 3




Body weight (g) 12.90 ± 0.98 11.02 ± 1.46
Heart rate (bmp) 456 ± 3 459 ± 7
Systolic function
Ejection fraction % 81.58 ± 3.94 81.43 ± 2.24
Fractional shortening % 49.64 ± 4.44 48.81 ± 2.23
Left coronary artery Pulse Doppler
LCA velocity time integral (cm) 2.12 ± 0.17 1.02 ± 0.10⁎⁎
LCA peak velocity (mm/s) 584.16 ± 46.44 342.83 ± 18.28⁎
LCA mean velocity (mm/s) 313.19 ± 22.51 179.13 ± 11.49⁎
LCA peak gradient (mm Hg) 1.39 ± 0.22 0.48 ± 0.55⁎
LCA mean gradient (mm Hg) 0.40 ± 0.06 0.13 ± 0.02⁎
Values are expressed as means ± SE from at least 8–10 mice per group. Statistical
signiﬁcance was determined by t tests. LCA, left coronary artery.
⁎ P b 0.05 compared to WT.
⁎⁎ P b 0.01 compared to WT.
Table 2
Cardiac function measurement with echocardiography in cTnI193His-M mice.
Wild type cTnI193His-M
Parameters
Body weight (g) 35.26 ± 0.45 34.44 ± 2.35
Heart rate (bpm) 481 ± 2 471 ± 17
Atria
LAEDD (mm) 2.10 ± 0.08 2.40 ± 0.11⁎
LAESD (mm) 1.40 ± 0.10 1.80 ± 0.19⁎
RAEDD (mm) 2.11 ± 0.11 2.33 ± 0.24
RAESD (mm) 1.56 ± 0.09 1.72 ± 0.02⁎
LV end diastole
IVS (mm) 0.73 ± 0.02 0.75 ± 0.02
LVEDD (mm) 3.64 ± 0.05 3.47 ± 0.03⁎
LV PW (mm) 0.76 ± 0.01 0.79 ± 0.02
LV volume (μl) 57.18 ± 2.36 53.35 ± 3.21
LV end systole
IVS (mm) 1.26 ± 0.02 1.28 ± 0.01
LVESD (mm) 1.89 ± 0.04 1.59 ± 0.09⁎
LV PW (mm) 1.27 ± 0.03 1.29 ± 0.01
LV volume (μl) 11.00 ± 0.56 12.79 ± 1.41
Ejection fraction % 80.28 ± 1.32 74.03 ± 1.10⁎
Fractional shortening % 48.16 ± 1.38 42.03 ± 0.93⁎
Mitral Pulse Doppler
E velocity (mm/s) 806.25 ± 31.45 734.03 ± 90.11
A velocity (mm/s) 664.39 ± 31.85 650.87 ± 70.35
E/A 1.21 ± 0.04 1.14 ± 0.14
LV IVRT (ms) 14.73 ± 0.45 21.17 ± 1.42⁎
LV IVCT (ms) 7.22 ± 0.29 9.94 ± 0.63⁎
Mitral TDI
E′ velocity (mm/s) 36.27 ± 3.03 22.5 ± 3.71⁎
A′ velocity (mm/s) 20.01 ± 6.36 22.13 ± 2.56
E′/A′ 1.33 ± 0.05 1.00 ± 0.07⁎
Values are expressed as means ± SE from at least 8–10 mice (8-month-old) per group.
Statistical signiﬁcance was determined by t tests.
⁎ P b 0.05 compared to WT.
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the cTnI mutation has a direct effect in the development of impaired
relaxation and RCM. The severity of the disease and the onset of theFig. 8.Measurement of coronary blood ﬂowwith Doppler echocardiography on RCM TGmice
ﬁrst peak) and diastolic stage (the second peak), were determined with Doppler echocardio
duced in cTnI193His-H mice at age of 23 days.overt signs of diastolic dysfunction or heart failure might be associated
with the levels of mutant protein in the heart.
RCM has been associated with a high rate of mortality especially in
the young. Ischemia is suspected to be a cause of sudden cardiac
death (SCD) in RCM patients. Rivenes et al. reported that ﬁve RCM pa-
tients presented with syncope, chest pain and ischemic ECG, which
were associated with their sudden death. Four hearts available for au-
topsy demonstrated evidences of acute and/or chronic ischemia in the
subendocardium and papillary muscle [7]. Another clinical study
performed by Palka et al. also reported the presence of ischemic signs
and the absence of chronic heart failure in RCM patients [22]. Hence,
the question whether ischemia is the cause of heart failure and SCD in
RCM is still open due to insufﬁcient histological evidence. The histolog-
ical examinations performed in this study on transgenic RCM mice at
different time points demonstrate the progressive formation of ﬁbrosis
in TG cardiac muscles, from the scattered ﬁbrosis in cardiac muscles in
TG hearts on day 23 to a massive ﬁbrosis formation in the TG hearts. Two peaks, representing the ﬂow in the left main coronary artery at systolic stage (the
graphy on wild type (WT) mice. The peak of coronary blood ﬂow was signiﬁcantly re-
Fig. 9. Telemetric ECG recordings on RCM TG mice. (A) The representative ECG recordings started on free-moving 3 wild type (WT) and 6 cTnI193His-H mice at age of 23 days and
continuously monitored for 3–4 days before death. (B) The ECG data show a depressed S–T segment in cTnI193His-H mice compared to that of WT.
235Y. Li et al. / Journal of Molecular and Cellular Cardiology 62 (2013) 227–236on day 27 (Fig. 7). ECG recordings also indicate ischemic signs such as
the alteration of S–T segment in RCM TG mice. More direct evidence is
the reduced coronary blood circulation observed by Doppler echocardi-
ography in these mice. It is also observed that the ischemic signs occur
after the impaired relaxation in the TG hearts, but before the overt sys-
tolic dysfunction (signiﬁcantly reduced ejection fraction and fractional
shortening) and heart failure (Table 3). It is well known that coronary
blood ﬂow occurs mostly during diastole and an increase of end-
diastolic pressure will decrease coronary artery blood ﬂow [23]. So it
is not without reason to expect an occurrence of myocardial ischemia
in a restricted heart since the elevated left ventricular pressure and
wall stress in RCM hearts can cause an increased extravascular com-
pressive force resulting in a reduced subendomyocardial perfusion.
The data from ECG recordings on RCM TGmice do not show signiﬁ-
cant arrhythmia. However, we did see arrhythmic signs on ECG from
RCM TG mice a couple of hours before death, which is probably due to
the disturbance of electrical activities in a late-stage failing heart. In
our study, we do not have sufﬁcient evidences to attribute arrhythmiato be a major cause for the early death observed in RCM TGmice. How-
ever, we cannot exclude the possible correlation between arrhythmia
and SCD in cardiomyopathy cases since arrhythmia is reported to be a
cause of SCD inHCM transgenicmicewith Ca2+ hypersensitivity caused
by ACTC gene mutation [29].
Heart failure related death is the most common outcome of cardio-
myopathies. RCM associated with sarcomere protein mutations seems
to cause more cases of severe heart failure compared to the RCM
resulting from other factors [24–28]. However, due to the rare incidence
of RCM and the lack of early screening indicators for the disease, there
are no completely tracked, large-scale clinical cases that are available
for an intensive survey on the clinical course of RCM. The RCM TG
mice provide us with a useful tool to investigate the mechanisms and
the disease development time-course by performing morphological
and functionalmeasurements at cellular, organ andwhole animal levels.
It is interesting to note that the preserved systolic function sometimes
becomes impaired at the end stage of RCM. Ammash et al. observed sys-
tolic dysfunction in 16% of 94 RCM patients [30]. Weller et al. reported a
236 Y. Li et al. / Journal of Molecular and Cellular Cardiology 62 (2013) 227–236low cardiac output in 18 RCM children [31]. Our data are consistentwith
these reports, suggesting that systolic heart failure occurs in the late
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